
Timothy D Warner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9090591/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full <i>in vitro</i> analysis. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7563-7568.	7.1	1,436
2	Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9797-9800.	7.1	1,293
3	Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10480-10484.	7.1	897
4	Isoforms of nitric oxide synthase Characterization and purification from different cell types. Biochemical Pharmacology, 1991, 42, 1849-1857.	4.4	813
5	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB Journal, 2004, 18, 790-804.	0.5	532
6	Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science, 1992, 255, 721-723.	12.6	419
7	Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circulation Research, 2013, 112, 595-600.	4.5	366
8	Coâ€induction of nitric oxide synthase and cycloâ€oxygenase: interactions between nitric oxide and prostanoids. British Journal of Pharmacology, 1995, 114, 1335-1342.	5.4	318
9	Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. Journal of Cardiovascular Pharmacology, 1989, 13, S85-88.	1.9	276
10	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. Journal of Immunology, 2009, 183, 2089-2096.	0.8	272
11	Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. European Journal of Pharmacology, 1989, 159, 325-326.	3.5	257
12	Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13371-13373.	7.1	252
13	Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2334-2338.	7.1	250
14	COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery, 2006, 5, 75-86.	46.4	235
15	Cycloâ€oxygenaseâ€2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. British Journal of Pharmacology, 1999, 128, 1121-1132.	5.4	234
16	Activation of PPARβ/δ Induces Endothelial Cell Proliferation and Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 63-69.	2.4	220
17	Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Molecular Pharmacology, 1992, 41, 615-24.	2.3	209
18	Expression and activation of the farnesoid X receptor in the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3668-3673.	7.1	203

#	Article	IF	CITATIONS
19	Antiâ€platelet therapy: cycloâ€oxygenase inhibition and the use of aspirin with particular regard to dual antiâ€platelet therapy. British Journal of Clinical Pharmacology, 2011, 72, 619-633.	2.4	172
20	Association of MicroRNAs and YRNAs With Platelet Function. Circulation Research, 2016, 118, 420-432.	4.5	167
21	Use of the endothelin antagonists BQâ€123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. British Journal of Pharmacology, 1993, 110, 777-782.	5.4	165
22	Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax, 2001, 56, 30-35.	5.6	163
23	The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression. Cancer Research, 2006, 66, 10120-10126.	0.9	157
24	In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis, 2011, 9, 552-561.	3.8	157
25	Endothelin-1 Release from Endothelial Cells in Culture Is Elevated Both Acutely and Chronically by Short Periods of Mechanical Stretch. Biochemical and Biophysical Research Communications, 1994, 200, 395-400.	2.1	147
26	Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2606-2611.	2.4	144
27	COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet, The, 2008, 371, 270-273.	13.7	143
28	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. Journal of Clinical Investigation, 2019, 129, 1845-1862.	8.2	136
29	Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. British Journal of Pharmacology, 1993, 109, 265-270.	5.4	126
30	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. British Journal of Pharmacology, 1993, 108, 776-779.	5.4	123
31	Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 706-711.	2.4	113
32	Cellular mechanisms of acetaminophen: role of cycloâ€oxygenase. FASEB Journal, 2005, 19, 1-15.	0.5	110
33	Effects of Cyclic GMP on Smooth Muscle Relaxation. Advances in Pharmacology, 1994, 26, 171-194.	2.0	106
34	Origins of Prostaglandin E2: Involvements of Cyclooxygenase (COX)-1 and COX-2 in Human and Rat Systems. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1001-1006.	2.5	105
35	Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17597-17602.	7.1	105
36	Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ. FASEB Journal, 2006, 20, 326-328.	0.5	101

#	Article	IF	CITATIONS
37	Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Molecular Pharmacology, 1999, 55, 902-9.	2.3	93
38	Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. British Journal of Pharmacology, 1997, 121, 125-133.	5.4	87
39	Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2691-2695.	7.1	82
40	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor Î ² Receptors in Prostacyclin Sensing by Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 242-246.	2.9	79
41	Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. British Journal of Pharmacology, 1999, 126, 1824-1830.	5.4	77
42	Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 104-110.	2.9	77
43	Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. British Journal of Pharmacology, 1990, 99, 427-433.	5.4	76
44	Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood, 2007, 109, 3741-3744.	1.4	75
45	A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. British Journal of Pharmacology, 1999, 127, 1589-1596.	5.4	74
46	The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 346, 919-925.	2.1	73
47	Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. Journal of Thrombosis and Haemostasis, 2010, 8, 613-615.	3.8	73
48	Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine. Circulation, 2015, 131, 633-642.	1.6	73
49	Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17444-17449.	7.1	73
50	Stronger inhibition by nonsteroid antiâ€inflammatory drugs of cyclooxygenaseâ€1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB Journal, 2006, 20, 2468-2475.	0.5	71
51	Role of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 384-391.	2.4	71
52	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. PLoS ONE, 2011, 6, e26591.	2.5	71
53	Selective COXâ $\in 2$ inhibitors and human inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 1999, 13, 1115-1117.	3.7	67
54	Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis, 2011, 9, 2103-2105.	3.8	66

#	Article	IF	CITATIONS
55	PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferatorâ€activated receptorâ€Î³ antagonist. FASEB Journal, 2003, 17, 1-15.	0.5	65
56	RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 247-252.	1.9	62
57	Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut, 2014, 63, 96-104.	12.1	62
58	Activation of peroxisome proliferator-activated receptor-Î ³ by troglitazone (TGZ) inhibits human lung cell growth. Journal of Cellular Biochemistry, 2005, 96, 760-774.	2.6	61
59	Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. Journal of Thrombosis and Haemostasis, 2008, 6, 1933-1943.	3.8	61
60	Evidence from receptor antagonists of an important role for ET _B receptorâ€mediated vasoconstrictor effects of endothelinâ€1 in the rat kidney. British Journal of Pharmacology, 1994, 111, 515-520.	5.4	60
61	Bisphenol A diglycidyl ether (BADGE) is a PPARÎ ³ agonist in an ECV304 cell line. British Journal of Pharmacology, 2000, 131, 651-654.	5.4	60
62	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 2014, 123, e11-e22.	1.4	60
63	Reversal of established responses to endothelinâ€1 <i>in vivo</i> and <i>in vitro</i> by the endothelin receptor antagonists, BQâ€123 and PD 145065. British Journal of Pharmacology, 1994, 112, 207-213.	5.4	59
64	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 949-956.	2.4	59
65	Intimal Smooth Muscle Cells as a Target for Peroxisome Proliferator-Activated Receptor-Î ³ Ligand Therapy. Circulation Research, 2002, 91, 210-217.	4.5	58
66	Role for Nuclear Factor-κB and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells. Molecular Pharmacology, 2003, 64, 923-931.	2.3	58
67	The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα In Vitro and In Vivo. PLoS ONE, 2009, 4, e7421.	2.5	58
68	Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. European Journal of Pharmacology, 1991, 204, 329-334.	3.5	56
69	Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4637-4642.	7.1	56
70	COX-2 Protects against Atherosclerosis Independently of Local Vascular Prostacyclin: Identification of COX-2 Associated Pathways Implicate Rgl1 and Lymphocyte Networks. PLoS ONE, 2014, 9, e98165.	2.5	56
71	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20483-20488.	7.1	55
72	Clopidogrel withdrawal: Is there a "rebound―phenomenon?. Thrombosis and Haemostasis, 2011, 105, 211-220.	3.4	55

#	Article	IF	CITATIONS
73	LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 Expression. PLoS ONE, 2013, 8, e69524.	2.5	54
74	Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochemical Pharmacology, 1990, 39, R21-R22.	4.4	53
75	COXâ€1, and not COXâ€2 activity, regulates airway function: relevance to aspirinâ€sensitive asthma. FASEB Journal, 2008, 22, 4005-4010.	0.5	53
76	The contribution of tumour necrosis factorâ€Î± and endothelinâ€1 to the increase of coronary resistance in hearts from rats treated with endotoxin. British Journal of Pharmacology, 1995, 116, 3309-3315.	5.4	52
77	Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo : investigations using the selective inhibitors, 1400W and celecoxib. British Journal of Pharmacology, 1998, 125, 335-340.	5.4	52
78	COX-2 in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 956-958.	2.4	52
79	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15812-15817.	7.1	52
80	Blockade of the purinergic P2Y ₁₂ receptor greatly increases the platelet inhibitory actions of nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15782-15787.	7.1	52
81	Comparative Studies with the Endothelin Receptor Antagonists BQ-123 and PD 142893 Indicate At Least Three Endothelin Receptors. Journal of Cardiovascular Pharmacology, 1993, 22, S117-S120.	1.9	50
82	Characterization of ET _B receptors mediating contractions induced by endothelinâ€1 or IRL 1620 in guineaâ€pig isolated airways: effects of BQâ€123, FR139317 or PD 145065. British Journal of Pharmacology, 1994, 111, 1009-1016.	5.4	49
83	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). British Journal of Pharmacology, 2019, 176, 988-999.	5.4	49
84	Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I2: Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 642-647.	2.5	48
85	Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovascular Research, 2012, 93, 674-681.	3.8	48
86	A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. American Journal of Physiology - Heart and Circulatory Physiology, 1991, 261, H598-H603.	3.2	47
87	Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach. British Journal of Pharmacology, 1994, 113, 1197-1202.	5.4	47
88	Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets, 2011, 22, 485-494.	2.3	47
89	4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 2011, 30, 106-116.	5.9	47
90	Nomenclature for COX-2 Inhibitors. Lancet, The, 2000, 356, 1373-1374.	13.7	46

#	Article	IF	CITATIONS
91	Effects of nonâ€steroidal antiâ€inflammatory drugs on cycloâ€oxygenase and lipoxygenase activity in whole blood from aspirinâ€sensitive asthmatics vs healthy donors. British Journal of Pharmacology, 2002, 137, 1031-1038.	5.4	46
92	Endothelial cells have a particulate enzyme system responsible for EDRF formation: Measurement by vascular relaxation. Biochemical and Biophysical Research Communications, 1991, 176, 1417-1423.	2.1	45
93	Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. Clinical and Experimental Immunology, 2002, 127, 263-269.	2.6	45
94	Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. British Journal of Pharmacology, 1993, 110, 687-692.	5.4	44
95	Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. British Journal of Pharmacology, 1995, 114, 1673-1679.	5.4	44
96	Synergy between cycloâ€oxygenaseâ€2 induction and arachidonic acid supply <i>in vivo</i> : consequences for nonsteroidal antiinflammatory drug efficacy. FASEB Journal, 1999, 13, 245-251.	0.5	44
97	Aspirin inhibits the production of proangiogenic 15(<i>S</i>)â€HETE by platelet cyclooxygenaseâ€1. FASEB Journal, 2016, 30, 4256-4266.	0.5	44
98	Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thrombosis and Haemostasis, 2009, 102, 772-778.	3.4	43
99	PPARβ/δ Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKCα–Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1871-1873.	2.4	43
100	Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochemical and Biophysical Research Communications, 2013, 438, 249-256.	2.1	43
101	Endothelin receptor antagonists: Actions and rationale for their development. Biochemical Pharmacology, 1994, 48, 625-635.	4.4	42
102	Influence of plasma protein on the potencies of inhibitors of cyclooxygenaseâ€1 and â€2. FASEB Journal, 2006, 20, 542-544.	0.5	41
103	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. Heart, 2010, 96, 1693-1694.	2.9	41
104	Regulation of Cyclo-oxygenase Gene Expression in Rat Smooth Muscle Cells by Catalase. Biochemical Pharmacology, 1998, 55, 1621-1631.	4.4	39
105	Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages. Molecular Pharmacology, 1992, 41, 1163-8.	2.3	39
106	Interleukin-1β, but not interleukin-6, enhances renal and systemic endothelin production in vivo. American Journal of Physiology - Renal Physiology, 2008, 295, F446-F453.	2.7	38
107	Cytokine and Lipopolysaccharide Stimulation of Endothelin-1 Release from Human Internal Mammary Artery and Saphenous Vein Smooth-Muscle Cells. Journal of Cardiovascular Pharmacology, 1998, 31, S348-S350.	1.9	38
108	Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. European Journal of Pharmacology, 1993, 250, 447-453.	3.5	37

#	Article	IF	CITATIONS
109	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. Vascular Pharmacology, 2015, 71, 70-78.	2.1	37
110	Different patterns of release of endotheliumâ€derived relaxing factor and prostacyclin. British Journal of Pharmacology, 1992, 105, 485-489.	5.4	36
111	Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse. PLoS ONE, 2011, 6, e20062.	2.5	36
112	Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guineaâ€pig ileum. British Journal of Pharmacology, 1993, 110, 783-789.	5.4	35
113	Cyclooxygenases and the cardiovascular system. , 2021, 217, 107624.		35
114	Endothelin Receptor Antagonists. Cardiovascular Drug Reviews, 1994, 12, 105-122.	4.1	34
115	What turns on the endothelins?. Inflammation Research, 1996, 45, 51-53.	4.0	33
116	Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart, 2011, 97, 1661-1667.	2.9	33
117	Roles of endothelin receptors in the regional and systemic vascular responses to ETâ€1 in the anaesthetized ganglionâ€blocked rat: use of selective antagonists. British Journal of Pharmacology, 1995, 116, 2482-2486.	5.4	32
118	Aspirin has little additional antiâ€platelet effect in healthy volunteers receiving prasugrel. Journal of Thrombosis and Haemostasis, 2011, 9, 2050-2056.	3.8	32
119	Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-lºB activation. Life Sciences, 1999, 64, 1231-1242.	4.3	31
120	Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. Platelets, 2012, 23, 404-408.	2.3	31
121	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 49-62.	2.4	31
122	Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guineaâ€pig. British Journal of Pharmacology, 1995, 115, 1319-1325.	5.4	30
123	The Prostacyclin-Mimetic Cicaprost Inhibits Endogenous Endothelin-1 Release From Human Pulmonary Artery Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S410-S413.	1.9	30
124	Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. European Journal of Medicinal Chemistry, 2001, 36, 517-530.	5.5	30
125	Inhibition of profibrotic microRNA-21 affects platelets and their releasate. JCI Insight, 2018, 3, .	5.0	30
126	Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. European Journal of Pharmacology, 2001, 426, 95-103.	3.5	29

#	Article	IF	CITATIONS
127	Loss of GPVI and GPIbα contributes to trauma-induced platelet dysfunction in severely injured patients. Blood Advances, 2020, 4, 2623-2630.	5.2	29
128	Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood, 2015, 126, e11-e18.	1.4	28
129	Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A ₂ Proves Renal Origins of Urinary PGI-M and TX-M. Circulation Research, 2018, 122, 555-559.	4.5	28
130	Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 948-952.	5.4	27
131	Characterization of endothelin (ET) receptors in the isolated gall bladder of the guineaâ€pig: evidence for an additional ET receptor subtype. British Journal of Pharmacology, 1994, 112, 1244-1250.	5.4	27
132	Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension. Molecular Pharmacology, 2002, 62, 1147-1153.	2.3	27
133	P2Y ₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British Journal of Clinical Pharmacology, 2016, 81, 621-633.	2.4	27
134	96-well plate-based aggregometry. Platelets, 2018, 29, 650-655.	2.3	27
135	Endothelin increases cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance. Journal of Pharmacology and Experimental Therapeutics, 1991, 259, 1102-8.	2.5	27
136	Inherited human group IVA cytosolic phospholipase A ₂ deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. FASEB Journal, 2015, 29, 4568-4578.	0.5	26
137	Endothelin versatility. Nature, 1995, 375, 539-540.	27.8	25
138	Gasotransmitters and platelets. , 2011, 132, 196-203.		25
139	Alkaline buffers release EDRF from bovine cultured aortic endothelial cells. British Journal of Pharmacology, 1991, 103, 1295-1302.	5.4	24
140	Human Big Endothelin Releases Prostacyclin in vivo and in vitro Through a Phosphoramidon-Sensitive Conversion to Endothelin-1. Journal of Cardiovascular Pharmacology, 1991, 17, S251-255.	1.9	24
141	Double-edged role of endogenous nitric oxide. Lancet, The, 1992, 339, 986.	13.7	24
142	Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. Free Radical Research, 2000, 32, 223-234.	3.3	24
143	Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sciences, 2002, 71, 1893-1904.	4.3	24
144	Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. Journal of Thrombosis and Haemostasis, 2009, 7, 1897-1905.	3.8	23

#	Article	IF	CITATIONS
145	Proteome and functional decline as platelets age in the circulation. Journal of Thrombosis and Haemostasis, 2021, 19, 3095-3112.	3.8	23
146	Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. Journal of Pharmacology and Experimental Therapeutics, 1999, 288, 1101-6.	2.5	23
147	Increased thromboxane B2 levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Letters, 2006, 234, 193-198.	7.2	22
148	Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Tollâ€ike receptor 4 responses in macrophages. British Journal of Pharmacology, 2010, 160, 1997-2007.	5.4	22
149	Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox. Circulation Research, 2019, 125, 847-854.	4.5	22
150	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S407-S409.	1.9	20
151	MODULATION BY COLONY STIMULATING FACTORS OF HUMAN EPITHELIAL COLON CANCER CELL APOPTOSIS. Cytokine, 2002, 20, 163-167.	3.2	20
152	Aspirinâ€triggered 15â€epiâ€lipoxin A ₄ predicts cyclooxygenaseâ€2 in the lungs of LPSâ€treated mic but not in the circulation: implications for a clinical test. FASEB Journal, 2013, 27, 3938-3946.	се 0.5	20
153	Vasoconstriction in the Rat Kidney Induced by Endothelin-1 Is Blocked by PD 145065. Journal of Cardiovascular Pharmacology, 1993, 22, S103-S106.	1.9	19
154	Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. European Journal of Pharmacology, 1997, 324, 219-222.	3.5	19
155	Platelet responses to pharmacological and physiological interventions in middleâ€aged men with different habitual physical activity levels. Acta Physiologica, 2018, 223, e13028.	3.8	18
156	The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. British Journal of Pharmacology, 1994, 112, 289-291.	5.4	17
157	Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9108-9110.	7.1	17
158	Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Experimental Cell Research, 2009, 315, 2974-2981.	2.6	17
159	Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1482-1493.	2.4	17
160	Effects of nitric oxide-modulating amino acids on coronary vessels: relevance to sepsis. European Journal of Pharmacology, 2000, 389, 209-215.	3.5	16
161	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2122-2133.	2.4	16
162	Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. Platelets, 2018, 29, 686-689.	2.3	16

#	Article	IF	CITATIONS
163	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
164	Human brain contains a metalloprotease that converts big endothelinâ€1 to endothelinâ€1 and is inhibited by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 505-506.	5.4	15
165	Human Platelets Utilize Cycloxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. Journal of Biological Chemistry, 2016, 291, 13448-13464.	3.4	15
166	Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. American Journal of Physiology - Heart and Circulatory Physiology, 1992, 262, H1600-H1605.	3.2	14
167	Synthesis and biological activity of the novel nitric oxide synthase inhibitor NI‰â€²-hydroxy-NI‰-methyl-L-arginine. Journal of the Chemical Society Perkin Transactions 1, 1994, , 769-771.	0.9	14
168	Endothelin-1 Mediates Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines. Journal of Cardiovascular Pharmacology, 1995, 26, S419-421.	1.9	14
169	Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. British Journal of Pharmacology, 2001, 134, 1237-1244.	5.4	13
170	High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thrombosis Research, 2013, 131, 313-319.	1.7	13
171	Characterization of endothelin-converting enzyme from endothelial cells and rat brain: detection of the formation of biologically active endothelin-1 by rapid bioassay. Molecular Pharmacology, 1992, 41, 399-403.	2.3	13
172	Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. Journal of Pharmacology and Experimental Therapeutics, 1995, 275, 120-6.	2.5	13
173	Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis, 2020, 120, 253-261.	3.4	12
174	Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. International Angiology, 1996, 15, 93-9.	0.9	12
175	Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 894-900.	2.5	12
176	Characterization of Serine Protease-Derived Metabolites of Big Endothelin in the Cytosolic Fraction from Human Polymorphonuclear Leukocytes. Journal of Cardiovascular Pharmacology, 1992, 20, S22-S24.	1.9	11
177	Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. European Journal of Pharmacology, 1994, 252, 341-345.	3.5	11
178	Inhibition of ETB Receptors Limits the Efficacy of Nonselective Endothelin Antagonists In Vivo. Journal of Cardiovascular Pharmacology, 1995, 26, S177-179.	1.9	11
179	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers. American Journal of Cardiovascular Drugs, 2012, 12, 217-224.	2.2	11
180	Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. British Journal of Pharmacology, 1995, 114, 867-871.	5.4	10

#	Article	IF	CITATIONS
181	Endothelinâ€l and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. British Journal of Pharmacology, 1996, 118, 21-26.	5.4	10
182	Cyclo-oxygenase-2 inhibitors and cardiovascular events. Lancet, The, 2002, 360, 1700-1701.	13.7	10
183	Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. British Journal of Cancer, 2002, 86, 1316-1321.	6.4	10
184	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregationin vitro: Insights using short thromboelastography. Platelets, 2015, 26, 689-692.	2.3	10
185	Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. Biochemical and Biophysical Research Communications, 2017, 484, 762-766.	2.1	10
186	Profiling the eicosanoid networks that underlie the anti―and proâ€ŧhrombotic effects of aspirin. FASEB Journal, 2020, 34, 10027-10040.	0.5	10
187	Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. Biochemical and Biophysical Research Communications, 1990, 172, 745-750.	2.1	9
188	Nitric oxide synthase in ferret brain: localization and characterization. British Journal of Pharmacology, 1992, 107, 849-852.	5.4	9
189	HIF, stretching to get control of VEGF. Clinical Science, 2003, 105, 393-394.	4.3	9
190	The Effect of NCX4016 [2-Acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl Ester] on the Consequences of Ischemia and Reperfusion in the Streptozotocin Diabetic Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1107-1114.	2.5	9
191	Comparison of the survival of endotheliumâ€derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat. British Journal of Pharmacology, 1989, 97, 777-782.	5.4	8
192	Detection by Bioassay and Specific Enzyme-Linked Immunosorbent Assay of Phosphoramidon-Inhibitable Endothelin-Converting Activity in Brain and Endothelium. Journal of Cardiovascular Pharmacology, 1992, 20, S19-S21.	1.9	7
193	Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. British Journal of Pharmacology, 1995, 116, 2787-2789.	5.4	7
194	Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 121-125.	3.0	7
195	Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet function. Haematologica, 2021, 106, 1423-1432.	3.5	7
196	Platelet inhibition by P2Y ₁₂ antagonists is potentiated by adenosine signalling activators. British Journal of Pharmacology, 2021, 178, 4758-4771.	5.4	7
197	Endothelin-1 Stimulates Cyclic GMP Formation in Porcine Kidney Epithelial Cells via Activation of the L-Arginine-Dependent Soluble Guanylate Cyclase Pathway. Journal of Cardiovascular Pharmacology, 1991, 17, S246-250.	1.9	6
198	ET touches down in Houston. Nature, 1993, 362, 497-498.	27.8	6

#	Article	IF	CITATIONS
199	NOS inhibitors in colitis: a suitable case for treatment?. Gut, 1998, 42, 152-153.	12.1	6
200	Cyclic AMP Regulates Cytokine Stimulation of Endothelin-1 Release in Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S404-S406.	1.9	6
201	NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. European Journal of Pharmacology, 2005, 508, 7-13.	3.5	6
202	IDENTIFICATION AND CHARACTERIZATION OF A DYSFUNCTIONAL CARDIAC MYOCYTE PHENOTYPE: ROLE OF BACTERIA, TOLL-LIKE RECEPTORS, AND ENDOTHELIN. Shock, 2007, 28, 434-440.	2.1	6
203	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. Expert Review of Hematology, 2016, 9, 223-225.	2.2	6
204	Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. Platelets, 2018, 29, 162-170.	2.3	6
205	5â€HT ₃ receptors do not mediate vagallyâ€induced relaxation or contraction of the isolated stomach of the guineaâ€pig. British Journal of Pharmacology, 1994, 111, 346-350.	5.4	5
206	Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats. European Journal of Pharmacology, 1996, 316, 245-247.	3.5	5
207	Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. Polish Journal of Pharmacology, 1994, 46, 587-92.	0.3	5
208	Coronary vasoconstriction <i>in vitro</i> in the hearts of polyarthritic rats: effectiveness of <i>in vivo</i> treatment with the endothelin receptor antagonist SB 209670. British Journal of Pharmacology, 1995, 114, 1327-1328.	5.4	4
209	Contractile activity of endothelin precursors in the isolated gallbladder of the guineaâ€pig: presence of an endothelinâ€converting enzyme. British Journal of Pharmacology, 1995, 114, 1383-1390.	5.4	4
210	Endothelin content, expression, and receptor type in normal and diseased human gallbladder. Digestive Diseases and Sciences, 2002, 47, 1786-1792.	2.3	4
211	Discontinuation of Vioxx. Lancet, The, 2005, 365, 27-28.	13.7	4
212	Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96â€well microtiter plates. Journal of Thrombosis and Haemostasis, 2009, 7, 1226-1228.	3.8	4
213	Smoking, atherothrombosis and clopidogrel. Heart, 2012, 98, 963-964.	2.9	4
214	Reply to Ricciotti et al.: Evidence for vascular COX isoforms. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E184-E184.	7.1	4
215	Regulation of blood pressure by l-arginine-nitric oxide pathway within the superior colliculus of rats. European Journal of Pharmacology, 1997, 328, 65-67.	3.5	3
216	Activation of ETa receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. Life Sciences, 1997, 60, PL271-PL276.	4.3	3

#	Article	IF	CITATIONS
217	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S407-S409.	1.9	3
218	Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment― Circulation Research, 2018, 122, e84-e85.	4.5	3
219	Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age. Circulation Research, 2020, 127, 394-396.	4.5	3
220	Combination of cyclic nucleotide modulators with P2Y 12 receptor antagonists as antiâ€platelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 1705-1713.	3.8	3
221	<i>Response</i> : Nitric Oxide and Arginine-Evoked Insulin Secretion. Science, 1992, 258, 1376-1378.	12.6	3
222	Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. European Heart Journal, 1993, 14 Suppl I, 42-7.	2.2	3
223	The Metabolism of Endothelin-1 and Big Endothelin-1 by the Isolated Perfused Kidney of the Rabbit. Journal of Cardiovascular Pharmacology, 1993, 22, S65-S68.	1.9	2
224	A Single Competitive Reverse Transcriptase-Polymerase Chain Reaction Assay to Measure Inducible Nitric Oxide Synthase Gene Expression in Both Human and Rat. Analytical Biochemistry, 1997, 247, 455-458.	2.4	2
225	Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. European Journal of Pharmacology, 2002, 440, 71-77.	3.5	2
226	Expression of the PIA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovascular Disease, 2015, 4, 204800401561025.	0.7	2
227	Reply to Letter Regarding Article, "Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugsâ€r Circulation, 2015, 132, e213-4.	1.6	2
228	A novel genetic variant in <scp><i>PTGS1</i></scp> affects Nâ€glycosylation of cyclooxygenaseâ€1 causing a dominantâ€negative effect on platelet function and bleeding diathesis. American Journal of Hematology, 2021, 96, E83-E88.	4.1	2
229	Shock news for the gut. Gut, 1998, 42, 606-606.	12.1	2
230	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. Pathology, 2022, 54, 746-754.	0.6	2
231	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. Methods, 1992, 1, 117-123.	0.5	1
232	N ^G -Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts. Endothelium: Journal of Endothelial Cell Research, 1995, 3, 121-129.	1.7	1
233	Short thromboelastography and the identification of high platelet reactivity while on and off therapy. Heart, 2012, 98, 679-680.	2.9	1
234	265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION:. Heart, 2013, 99, A139.3-A140.	2.9	1

#	Article	IF	CITATIONS
235	261 P2Y12 INHIBITION GREATLY POTENTIATES THE ANTI-PLATELET EFFECTS OF PROSTACYCLIN AND NITRIC OXIDE. Heart, 2013, 99, A137.2-A138.	2.9	1
236	Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. BMJ Open, 2015, 5, e005750-e005750.	1.9	1
237	Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Canadian Journal of Physiology and Pharmacology, 2017, 95, 954-960.	1.4	1
238	Irish society for gastroenterology. Irish Journal of Medical Science, 1994, 163, 37-47.	1.5	0
239	The molecular and biological basis for COX-2 selectivity. , 2004, , 41-65.		0
240	46 Urinary prostanoid metabolites in healthy volunteers taking prasugrel and aspirin. Heart, 2011, 97, e7-e7.	2.9	0
241	12 Relationship between proportions of P2Y12 inhibited platelets and aggregation in vitro. Heart, 2011, 97, e7-e7.	2.9	0
242	30 Investigation of the action of prostaglandin E2 on human platelets. Heart, 2011, 97, e7-e7.	2.9	0
243	22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel. Heart, 2011, 97, e7-e7.	2.9	0
244	207 PLATELET COX-1 SUPPORTS THE PRODUCTION OF BOTH PROSTANOIDS AND HETES. Heart, 2013, 99, A114.1-A114.	2.9	0
245	236 DURING ANTI-PLATELET THERAPY PLATELET TURNOVER MAY LEAD TO THE EMERGENCE OF A MINORITY OF UNINHIBITED PLATELETS SUFFICIENT TO INITIATE AND DRIVE PLATELET AGGREGATE FORMATION. Heart, 2013, 99, A126.2-A127.	2.9	0
246	In celebration of Professor Gus Born's life, 29 July 1921 – 16 April 2018. Platelets, 2018, 29, 743-743.	2.3	0
247	Cox2 reporter gene expression and prostacylin mass spectrometry confirm vascular COXâ€1 dominance for prostacyclin production. FASEB Journal, 2013, 27, lb507.	0.5	0
248	<i>Response</i> : Nitric Oxide and Arginine-Evoked Insulin Secretion. Science, 1992, 258, 1376-1378.	12.6	0
249	Endothelins: Recent Progress. , 1995, , 313-318.		0
250	Cytokine Regulation of Endothelin Action. , 1998, , 89-100.		0
251	The Development of Specific Endothelin-Receptor Antagonists. , 1998, , 189-222.		0

252 Endothelin Receptors and Ligands. , 1999, , 21-48.

#	Article	IF	CITATIONS
253	Nitric oxide and endothelin-1 in circulatory shock involving cytokines. , 1999, , 151-171.		0
254	Understanding the cardiovascular effects of low dose aspirin by using a platelet COX-1-/- mouse model. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-2-57.	0.0	0
255	Platelet reactivity in an elderly and healthy population. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR25-2.	0.0	Ο
256	Endothelin-1 Mediates the Increase in Ex Vivo Coronary Vascular Resistance Induced by Hemorrhagic Shock in the Anesthetized Rat. Journal of Cardiovascular Pharmacology, 1995, 26, S422-424.	1.9	0